Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294678345> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W4294678345 endingPage "ii72" @default.
- W4294678345 startingPage "ii72" @default.
- W4294678345 abstract "Abstract Background Glioblastomas with methylation of the promotor region of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene exhibit increased sensitivity to alkylating chemotherapy. Quantitative assessment of the MGMT promotor methylation status might provide additional prognostic information. The aim of our study was to determine a quantitative threshold of MGMT methylation for better survival among patients with isocitrate dehydrogenase (IDH) wildtype glioblastomas. Material and Methods We included consecutive patients treated at our department between 11/2010 and 08/2018. Inclusion criteria were i) diagnosis of glioblastoma, IDH wildtype according to the 2021 WHO classification of tumors of the central nervous system, ii) availability of a quantitative MGMT promotor methylation analysis, iii) absence of an IDH mutation as determined by immunohistochemistry and/or sequencing, and iii) age ≥ 18 years. The primary endpoint was overall survival. To evaluate a threshold for a benefit from temozolomide (TMZ), a secondary analysis included only tumors exposed to TMZ, which were compared to a historical cohort treated by radiotherapy only with a median survival of 13.0 months. Results Between 11/2010 and 08/2018, 321 patients diagnosed with a glioblastoma, IDH wildtype meeting our inclusion criteria were included. Mean age at diagnosis was 64.1 years (± 11.4). Median overall survival was 12.6 months. Kaplan-Meier analysis showed better survival for all groups with ≥ 16% methylation. Similarly, Cox regression analysis confirmed significantly better survival in the groups with 16-30%, 31-60%, and 61-100% methylation. In contrast, survival in the group with 1-15% methylation was similar to that with unmethylated promotor regions. When the percentage of methylation of each patient treated with TMZ was plotted on an ROC curve using survival > 13.0 months as outcome parameter, the Youden index was maximal at ≥ 16% methylation. Conclusion Better survival is seen in patients with glioblastomas with ≥ 16% methylation of the MGMT promotor region than with < 16% methylation. Survival with tumors with 1-15% methylation is similar to with unmethylated tumors. Above 16% methylation, we found no additional benefit with increasing methylation." @default.
- W4294678345 created "2022-09-06" @default.
- W4294678345 creator A5008487905 @default.
- W4294678345 creator A5018689848 @default.
- W4294678345 creator A5022871416 @default.
- W4294678345 creator A5030272372 @default.
- W4294678345 creator A5031816249 @default.
- W4294678345 creator A5037125229 @default.
- W4294678345 creator A5057526328 @default.
- W4294678345 creator A5087123540 @default.
- W4294678345 creator A5090936485 @default.
- W4294678345 date "2022-09-01" @default.
- W4294678345 modified "2023-09-27" @default.
- W4294678345 title "P11.60.A Quantitative analysis of the MGMT methylation status of glioblastomas in the light of the 2021 WHO classification" @default.
- W4294678345 doi "https://doi.org/10.1093/neuonc/noac174.249" @default.
- W4294678345 hasPublicationYear "2022" @default.
- W4294678345 type Work @default.
- W4294678345 citedByCount "0" @default.
- W4294678345 crossrefType "journal-article" @default.
- W4294678345 hasAuthorship W4294678345A5008487905 @default.
- W4294678345 hasAuthorship W4294678345A5018689848 @default.
- W4294678345 hasAuthorship W4294678345A5022871416 @default.
- W4294678345 hasAuthorship W4294678345A5030272372 @default.
- W4294678345 hasAuthorship W4294678345A5031816249 @default.
- W4294678345 hasAuthorship W4294678345A5037125229 @default.
- W4294678345 hasAuthorship W4294678345A5057526328 @default.
- W4294678345 hasAuthorship W4294678345A5087123540 @default.
- W4294678345 hasAuthorship W4294678345A5090936485 @default.
- W4294678345 hasBestOaLocation W42946783451 @default.
- W4294678345 hasConcept C104317684 @default.
- W4294678345 hasConcept C10515644 @default.
- W4294678345 hasConcept C126322002 @default.
- W4294678345 hasConcept C143998085 @default.
- W4294678345 hasConcept C150194340 @default.
- W4294678345 hasConcept C181199279 @default.
- W4294678345 hasConcept C190727270 @default.
- W4294678345 hasConcept C2776694085 @default.
- W4294678345 hasConcept C2777150147 @default.
- W4294678345 hasConcept C2777389519 @default.
- W4294678345 hasConcept C2779527866 @default.
- W4294678345 hasConcept C33288867 @default.
- W4294678345 hasConcept C50382708 @default.
- W4294678345 hasConcept C54355233 @default.
- W4294678345 hasConcept C55493867 @default.
- W4294678345 hasConcept C71924100 @default.
- W4294678345 hasConcept C86803240 @default.
- W4294678345 hasConcept C91965660 @default.
- W4294678345 hasConceptScore W4294678345C104317684 @default.
- W4294678345 hasConceptScore W4294678345C10515644 @default.
- W4294678345 hasConceptScore W4294678345C126322002 @default.
- W4294678345 hasConceptScore W4294678345C143998085 @default.
- W4294678345 hasConceptScore W4294678345C150194340 @default.
- W4294678345 hasConceptScore W4294678345C181199279 @default.
- W4294678345 hasConceptScore W4294678345C190727270 @default.
- W4294678345 hasConceptScore W4294678345C2776694085 @default.
- W4294678345 hasConceptScore W4294678345C2777150147 @default.
- W4294678345 hasConceptScore W4294678345C2777389519 @default.
- W4294678345 hasConceptScore W4294678345C2779527866 @default.
- W4294678345 hasConceptScore W4294678345C33288867 @default.
- W4294678345 hasConceptScore W4294678345C50382708 @default.
- W4294678345 hasConceptScore W4294678345C54355233 @default.
- W4294678345 hasConceptScore W4294678345C55493867 @default.
- W4294678345 hasConceptScore W4294678345C71924100 @default.
- W4294678345 hasConceptScore W4294678345C86803240 @default.
- W4294678345 hasConceptScore W4294678345C91965660 @default.
- W4294678345 hasIssue "Supplement_2" @default.
- W4294678345 hasLocation W42946783451 @default.
- W4294678345 hasOpenAccess W4294678345 @default.
- W4294678345 hasPrimaryLocation W42946783451 @default.
- W4294678345 hasRelatedWork W1995740954 @default.
- W4294678345 hasRelatedWork W2035040889 @default.
- W4294678345 hasRelatedWork W2335501790 @default.
- W4294678345 hasRelatedWork W2341293679 @default.
- W4294678345 hasRelatedWork W2887431954 @default.
- W4294678345 hasRelatedWork W2959679962 @default.
- W4294678345 hasRelatedWork W4200606830 @default.
- W4294678345 hasRelatedWork W4294678345 @default.
- W4294678345 hasRelatedWork W4306404899 @default.
- W4294678345 hasRelatedWork W4307423039 @default.
- W4294678345 hasVolume "24" @default.
- W4294678345 isParatext "false" @default.
- W4294678345 isRetracted "false" @default.
- W4294678345 workType "article" @default.